Milanovski, Gorjan
Preferred name
Milanovski, Gorjan
Official Name
Milanovski, Gorjan
Translated Name
Милановски, Горјан
Alternative Name
Milanovski G.
G. Milanovski
Milanovski Gorjan
Gorjan Milanovski
Main Affiliation
7 results
Now showing 1 - 7 of 7
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, COMPARISON OF TWO METHODS FOR SARS-COV-2 ANTIBODY TESTING(University Ss. Cyril and Methodius in Skopje, 2022); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PREVALENCE OF ANTI-SARS-COV-2 IGG ANTIBODIES IN SKOPJE, NORTH MACEDONIA: TWO-TIME POINTS POPULATION-BASED CROSS-SECTIONAL STUDY(University Ss. Cyril and Methodius in Skopje, 2023); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Semilobar Holoprosencephaly Caused by a Novel and De Novo ZIC2 Pathogenic Variant(Walter de Gruyter GmbH, 2023-05); ; ; Muaremoska-Kanzoska, LjeljaHoloprosencephaly (HPE) is the most common embryonic forebrain developmental anomaly. It involves incomplete or absent division of the prosencephalon into two distinct cerebral hemispheres during the early stages of organogenesis. HPE is etiologically heterogeneous, and its clinical presentation is very variable. We report a case of a 7 month old female infant, diagnosed with non-syndromic semilobar holoprosencephaly, caused by a novel, de novo pathogenic variant in ZIC2 - one of the most commonly mutated genes in non-syndromic HPE coding for the ZIC2 transcription factor. The patient presented with microcephaly, mild facial dysmorphic features, central hypotonia and spasticity on all four extremities. Ultrasound imaging demonstrated the absence of septum pellucidum, semilobar fusion of the hemispheres and mega cisterna magna and brain MRI with confirmed the diagnosis of HPE. Early diagnosis and management are important for the prevention and treatment of complications associated with this condition. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparison between the homologous BNT162b2 and the heterologous Gam-COVID-Vac/BNT162b2 vaccine regimen in republic of North Macedonia(Croatian Society of Biologists in Health Care, 2022-12-16); ; ; <jats:p>The medical and socio-economic consequences that stemmed from the COVID-19 pandemic, forced the healthcare policymakers in Republic of North Macedonia to rely on five different vaccines against the SARS-CoV-2 virus, in order to reach a satisfactory level of herd immunity. It is here where we got the idea to compare the heterologous Gam-COVID-Vac/BNT162b2 regimen to the homologous BNT162b2 regimen, with our main focus being the immunogenicity differences between the two of them. Additionally, we researched the variation in humoral immune response relative to age strata; the reactogenicity differences; and discrepancies in SARS-CoV-2 infection incidence between the two regimens. To achieve this, antibody titers in sera samples from fifty-three (53) healthcare workers, divided in heterologous and homologous group, were analysed at six different time checkpoints. Our results showed robust immunogenic response after the administration of the booster dose (4. 2-fold increase in antibody titers), followed by a slower-waning humoral immune protection in the heterologous regimen, compared to the homologous BNT162b2 schedule, furthermore confirmed by non-inferiority testing (Geometric Mean Ratio=0,98) at the final checkpoint. That, coupled with the similar reactogenicity (p=0,767) of both regimens, imply that the Gam-COVID-Vac/BNT162b2 combination might be a feasible approach in the effort to contain the COVID-19 pandemic.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, TYPE OF CYP450 2C19 GENE METABOLIZERS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN THE REPUBLIC OF NORTH MACEDONIA -A PILOT STUDY(University Ss. Cyril and Methodius in Skopje, 2022); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A single dose of BNT162b2 vaccine elicits strong humoral response in SARS-CoV-2 seropositive individuals(Wiley, 2022-01); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication,